COMPOSITIONS AND METHODS OF USING R(+) PRAMIPEXOLE
Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed.
1 . A method of treating age-related macular degeneration comprising administering a therapeutically effective amount of R(+) pramipexole.
2 . The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is administered in a pharmaceutical composition.
3 . The method of claim 2 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 80% or greater.
4 . The method of claim 2 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 90% or greater.
5 . The method of claim 2 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 95% or greater.
6 . The method of claim 2 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 99% or greater.
7 . The method of claim 1 , wherein said the therapeutically effective amount of R(+) pramipexole is from about 50 milligrams to about 5000 milligrams.
8 . The method of claim 1 , wherein the therapeutically effective amount of R(+) pramipexole is from about 100 milligrams to about 3000 milligrams.
9 . The method of claim 1 , wherein the therapeutically effective amount of R(+) pramipexole is from about 300 milligrams to about 1500 milligrams.
10 . The method of claim 1 , wherein the therapeutically effective amount of R(+) pramipexole is from about 500 milligrams to about 1000 milligrams.
11 . The method of claim 2 , wherein said pharmaceutical composition is suitable for oral administration.
12 . The method of claim 2 , wherein said pharmaceutical composition is a solid oral dosage form.
13 . The method of claim 2 , wherein said pharmaceutical composition is a tablet.
14 . The method of claim 2 , wherein said pharmaceutical composition is a capsule.
15 . The method of claim 2 , wherein said pharmaceutical composition is a suitable for ocular administration.
16 . The method of claim 2 , wherein said pharmaceutical composition further comprises S(−) pramipexole in an amount that does not provide significant dopamine agonist activity.
17 . The method of claim 2 , wherein said pharmaceutical composition consists essentially of R(+) pramipexole.
18 . The method of claim 2 , wherein said pharmaceutical compositions further comprises an agent useful in treating age-related macular degeneration.
19 . A method of treating of treating type II diabetes comprising administering a therapeutically effective amount of R(+) pramipexole.
20 . The method of claim 19 , wherein said therapeutically effective amount of R(+) pramipexole is administered in a pharmaceutical composition.
21 . The method of claim 20 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 80% or greater.
22 . The method of claim 20 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 90% or greater.
23 . The method of claim 20 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 95% or greater.
24 . The method of claim 20 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 99% or greater.
25 . The method of claim 19 , wherein said the therapeutically effective amount of R(+) pramipexole is from about 50 milligrams to about 5000 milligrams.
26 . The method of claim 19 , wherein the therapeutically effective amount of R(+) pramipexole is from about 100 milligrams to about 3000 milligrams.
27 . The method of claim 19 , wherein the therapeutically effective amount of R(+) pramipexole is from about 300 milligrams to about 1500 milligrams.
28 . The method of claim 19 , wherein the therapeutically effective amount of R(+) pramipexole is from about 500 milligrams to about 1000 milligrams.
29 . The method of claim 20 , wherein said pharmaceutical composition is suitable for oral administration.
30 . The method of claim 20 , wherein said pharmaceutical composition is a solid oral dosage form.
31 . The method of claim 20 , wherein said pharmaceutical composition is a tablet.
32 . The method of claim 20 , wherein said pharmaceutical composition is a capsule.
33 . The method of claim 20 , wherein said pharmaceutical composition further comprises S(−) pramipexole in an amount that does not provide significant dopamine agonist activity.
34 . The method of claim 20 , wherein said pharmaceutical composition consists essentially of R(+) pramipexole.
35 . The method of claim 20 , wherein said pharmaceutical composition further comprises an agent useful in treating type II diabetes.
36 . A method of treating of treating skin disorders comprising administering a therapeutically effective amount of R(+) pramipexole.
37 . The method of claim 36 , wherein said therapeutically effective amount of R(+) pramipexole is administered in a pharmaceutical composition.
38 . The method of claim 37 , wherein said pharmaceutical composition has a chiral purity of the R(+) enantiomer of pramipexole of 80% or greater.
39 . The method of claim 37 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 90% or greater.
40 . The method of claim 37 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 95% or grater.
41 . The method of claim 37 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 99% or greater.
42 . The method of claim 36 , wherein said the therapeutically effective amount of R(+) pramipexole is from about 50 milligrams to about 5000 milligrams.
43 . The method of claim 36 , wherein the therapeutically effective amount of R(+) pramipexole is from about 100 milligrams to about 3000 milligrams.
44 . The method of claim 36 , wherein the therapeutically effective amount of R(+) pramipexole is from about 300 millgrams to about 1500 milligrams.
45 . The method of claim 36 , wherein the therapeutically effective amount of R(+) pramipexole is from about 500 milligrams to about 1000 milligrams.
46 . The method of claim 37 , wherein said pharmaceutical composition is suitable for oral administration.
47 . The method of claim 37 , wherein said pharmaceutical composition is a solid oral dosage form.
48 . The method of claim 37 , wherein said pharmaceutical composition is a tablet.
49 . The method of claim 37 , wherein said pharmaceutical competition is a capsule.
50 . The method of claim 37 , wherein said pharmaceutical composition is suitable for topical administration.
51 . The method of claim 37 , wherein said pharmaceutical composition further comprises S(−) pramipexole in an amount that does not provide significant dopamine agonist activity.
52 . The method of claim 37 , wherein said pharmaceutical consists essentially of R(+) pramipexole.
53 . The method of claim 37 , wherein the pharmaceutical compositions further comprises an agent useful in treating skin disorders.
54 . A method of treating of treating cardiovascular disorders comprising administering a therapeutically effective amount of R(+) pramipexole.
55 . The method of claim 54 , wherein said therapeutically effective amount of R(+) pramipexole is administered in a pharmaceutical composition.
56 . The method of claim 55 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 80% or greater.
57 . The method of claim 55 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 90% or greater.
58 . The method of claim 55 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 95% or greater.
59 . The method of claim 55 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 99% or greater.
60 . The method of claim 54 , wherein said the therapeutically effective amount of R(+) pramipexole is from about 50 milligrams to about 5000 milligrams.
61 . The method of claim 54 , wherein the therapeutically effective amount of R(+) pramipexole is from about 100 milligrams to about 3000 milligrams.
62 . The method of claim 54 , wherein the therapeutically effective amount of R(+) pramipexole is from about 300 milligrams to about 1500 milligrams.
63 . The method of claim 54 , wherein the therapeutically effective amount of R(+) pramipexole is from about 500 milligrams to about 1000 milligrams.
64 . The method of claim 55 , wherein said pharmaceutical composition is suitable for oral administration.
65 . The method of claim 55 , wherein said pharmaceutical composition is a solid oral dosage form.
66 . The method of claim 55 , wherein said pharmaceutical composition is a tablet.
67 . The method of claim 55 , wherein said pharmaceutical composition is a capsule.
68 . The method of claim 55 , wherein said pharmaceutical composition further comprises S(−) pramipexole in an amount that does not provide significant dopamine agonist activity.
69 . The method of claim 55 , wherein said pharmaceutical composition consists essentially of R(+) pramipexole.
70 . The method of claim 55 , wherein the pharmaceutical compositions further comprises an agent useful in treating cardiovascular disorders.
71 . A method of treating of treating inflammatory disorders comprising administering a therapeutically effective amount of R(+) pramipexole.
72 . The method of claim 71 , wherein said therapeutically effective amount of R(+) pramipexole is administered in a pharmaceutical composition.
73 . The method of claim 72 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 80% or greater.
74 . The method of claim 72 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 90% or greater.
75 . The method of claim 72 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 95% or greater.
76 . The method of claim 72 , wherein said pharmaceutical composition has a chiral purity for the R(+) enantiomer of pramipexole of 99% or greater.
77 . The method of claim 71 , wherein said the therapeutically effective amount of R(+) pramipexole is from about 50 milligrams to about 5000 milligrams.
78 . The method of claim 71 , wherein the therapeutically effective amount of R(+) pramipexole is from about 100 milligrams to about 3000 milligrams.
79 . The method of claim 71 , wherein the therapeutically effective amount of R(+) pramipexole is from about 300 milligrams to about 1500 milligrams.
80 . The method of claim 71 , wherein the therapeutically effective amount of R(+) pramipexole is from about 500 milligrams to about 1000 milligrams.
81 . The method of claim 72 , wherein said pharmaceutical composition is suitable for oral administration.
82 . The method of claim 72 , wherein said pharmaceutical composition is a solid oral dosage form.
83 . The method of claim 72 , wherein said pharmaceutical composition is a tablet.
84 . The method of claim 72 , wherein said pharmaceutical composition further comprises S(−) pramipexole in an amount that does not provide significant dopamine agonist activity.
85 . The method of claim 72 , wherein said pharmaceutical composition consists essentially of R(+) pramipexole.
86 . The method of claim 72 , wherein the pharmaceutical compositions further comprises an agent useful in treating inflammatory disorders.